ArticleFrontiers in oncology2026
Efficacy and safety of combining TACE with atezolizumab/bevacizumab versus TACE alone: a retrospective propensity score-matched cohort study in HBV-related hepatocellular carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transarterial chemoembolization (TACE) is an established treatment for intermediate to advanced hepatocellular carcinoma (HCC) in China, where chronic hepatitis B virus (HBV) infection constitutes the primary etiology. Although the use of TACE combined with atezolizumab/bevacizumab (TACE+TA) is increasing, robust evidence regarding its efficacy and safety-including the risk of HBV reactivation-remains limited in this etiologically distinct population. Methods: This retrospective analysis included 246 patients with HBV-related HCC treated between 2020 and 2024. Patients were stratified according to the treatment received: TACE monotherapy (n = 113) or TACE+TA (n = 133). The primary endpoints were overall survival (OS) and progression-free survival (PFS). Tumor response was assessed using the modified Response Evaluation Criteria in Solid Tumors (mRECIST). To minimize selection bias, a 1:1 propensity score matching (PSM) analysis was performed. Results: After matching, patients receiving TACE+TA achieved superior outcomes compared with TACE monotherapy, with prolonged median OS (19 vs. 13 months; Conclusions: In patients with HBV-related HCC, TACE+TA confers a significant survival advantage over TACE monotherapy, albeit with an increased risk of HBV reactivation and immune-related adverse events. This finding underscores the need for rigorous antiviral prophylaxis and close monitoring in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.